enGene Therapeutics Inc. cotiza a 1.63 USD y tiene una capitalización bursátil de $109M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasi…
| Periodo | 2026-12 | 2026-09 | 2026-06 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.47 | $-0.43 | $-0.44 |
| Estimado | $-0.46 | $-0.43 | $-0.47 | $-0.57 |
| Sorpresa | — | -9.3% | +8.5% | +22.8% |
| Métrica | ENGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -69.9% | -40.4% | -29.5% |
| ROA | -53.0% | -32.0% | -21.0% |
| Current Ratio | 6.30 | 2.84 | +3.46 |
| Debt / Equity | 0.09 | 0.28 | -0.19 |